Slide 1: 3Q22 Earnings Presentation
3Q22 Earnings Presentation October 28, 2022
Slide 2: Disclaimer
Disclaimer Forward-looking statements are exclusively related to the prospects of the business, its operating and financial results, and prospects for growth. These data are merely projections and, as such, based exclusively on our management's expectations for the future of the business and its con
Slide 3: 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22
4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 3
Slide 4: Main Launches in 3Q22
Main Launches in 3Q22 Interest on Equity of R$194.8 million (R$O.31/share) in 3Q22 &) Affinity groups focusing on minorities ESG Health efforts in Sado Paulo and Anapolis aad Compliance Day +21% in Standard & Poor's ESG ranking score in the last year TI Sr vpera
Slide 5: Non-retail Market
Non-retail Market Net Revenue of R$100.9 million, compared to R$34.9 million in 3Q21 Launch of the antibiotics CEFEPIME, CEFUROXIM and BAC-SULFITRIN New injectables plant launched in Andpolis-GO @PHypera pharma
Slide 6: 3Q22 Results (R$ million)
3Q22 Results (R$ million) NET REVENUE R$2,035.8 424.7%! GROSS MARGIN 63.5%? -40bps! MARKETING EXPENSES 16.1%? -70bps' SELLING EXPENSES 10.1%? -80bps' GENERAL AND ADMINISTRATIVE EXPENSES 4.1%? +50bps! EBITDA MARGIN FROM CONTINUING OP. (excl. OTHERS) 35.5%? +60bps! NET INCOME FROM CONTINUING OPERATION
Slide 7: Cash flow and net debt
2Q22 Gross Cash Flow from CAPEX Intangibles 3Q22 Free Cash Financing Cash IOC 3Q22 Gross 3Q22 Gross 3Q22 Net Debt Cash Operations Flow Flow Cash Debt
Slide 8: Slide 8